Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Marvell Technology Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Marvell Technology Inc trades at $239.36 (market cap $220.43B). The key difference: Marvell Technology Inc is far larger — about 24.8× Kymera Therapeutics Inc. Common Stock's market cap, and Marvell Technology Inc pays a 0.1% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Marvell Technology Inc for 43 Days on average.
| KYMR | MRVL | |
|---|---|---|
Market Cap | $8.88B | $220.43B |
Volume | 1,028,790 | 25,874,039 |
Sector | Health | Technology |
52-Week High | $127.31 | $316.43 |
52-Week Low | $55.80 | $73.73 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $8.27B | $221.79B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marvell Technology (MRVL) trades at $268.73, up 1.08% today, with a bullish technical signal from moving averages and strong analyst support. The company reported three consecutive quarterly EPS beats and projects robust revenue growth, driven by AI and data center demand. Recent news highlights a $120 billion potential deal with Google and raised fiscal 2028 guidance to $18 billion, fueling investor optimism despite high valuation multiples.
Outlook remains positive with a consensus price target of $327.86, implying 22% upside, but risks include elevated P/E of 88.98 and dependence on hyperscaler contracts. Net losses in 2025 contrast with projected 2026 profitability, requiring execution on custom chip growth to justify valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
